Physician profile
Samuel E Koszer
NPI 1982697975
$16,464.06
in general payments reported to CMS, 2019-2025
44 companies · $1,907 in 2025
The $1,907 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,436 · 2020: $203 · 2021: $294 · 2022: $1,393 · 2023: $1,388 · 2024: $1,843 · 2025: $1,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,659 · Education: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,658.91 |
| Education | $479.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $9,837.26 | 2019-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $1,184.32 | 2022-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $1,093.32 | 2021-2025 | |
| Ucb, INC. | $505.71 | 2023-2025 | Nayzilam, Fintepla, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $422.64 | 2020-2025 | |
| Jazz Pharmaceuticals INC. | $405.38 | 2019-2025 | Xywav |
| Harmony Biosciences LLC | $378.89 | 2021-2025 | Wakix |
| Neurelis, INC. | $278.86 | 2021-2025 | Valtoco |
| Genentech USA, INC. | $221.79 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Pfizer INC. | $210.54 | 2023-2025 | |
| Argenx US, INC. | $192.28 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $174.21 | 2022-2025 | |
| Janssen Biotech, INC. | $130.16 | 2025 | |
| Janssen Pharmaceuticals, INC | $126.00 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $104.30 | 2022-2025 | Ultomiris, Soliris |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $91.96 | 2019-2025 | |
| Monteris Medical Corporation | $91.63 | 2019 | |
| Celgene Corporation | $90.44 | 2022-2025 | Zeposia |
| Biogen, INC. | $89.92 | 2019-2025 | Skyclarys, Tysabri, Vumerity |
| Takeda Pharmaceuticals U.S.A., INC. | $78.93 | 2023-2024 | Hyqvia |
| Sunovion Pharmaceuticals INC. | $70.27 | 2019-2020 | |
| Lundbeck LLC | $62.11 | 2022-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $61.58 | 2019-2020 | |
| Grifols USA, LLC | $55.25 | 2024-2025 | Gamunex-C |
| Tg Therapeutics, INC. | $46.59 | 2023 | |
| Livanova USA, INC. | $39.00 | 2019 | |
| Alnylam Pharmaceuticals INC. | $34.68 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $33.49 | 2025 | Wainua |
| Idorsia Pharmaceuticals US INC | $30.53 | 2023 | Quviviq |
| Amgen INC. | $28.77 | 2021-2024 | Aimovig |
| Axsome Therapeutics, INC. | $25.25 | 2024 | Sunosi |
| Lilly USA, LLC | $25.20 | 2024 | Amyvid |
| Vanda Pharmaceuticals INC. | $24.72 | 2025 | Ponvory |
| Merz Pharmaceuticals, LLC | $23.89 | 2025 | Xeomin, Inbrija, Ampyra |
| Impel Pharmaceuticals INC. | $23.57 | 2023 | Trudhesa |
| Insightec,INC | $23.55 | 2025 | Exablate |
| Octapharma USA, INC. | $23.14 | 2024 | Panzyga |
| Spr Therapeutics, INC | $22.87 | 2025 | Sprint Pns System |
| Genentech, INC. | $21.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.50 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $16.49 | 2025 | Rexulti |
| Medtronic USA, INC. | $14.60 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $14.58 | 2023 | Fycompa |
| Zogenix INC. | $14.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Koszer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.